CAJ | 학술논문

目的：体外探讨EGFR抑制剂埃罗替尼（Erlotinib）对肾上腺皮质癌SW13细胞的增殖、凋亡及细胞周期的影响。方法应用M T T试验观察埃罗替尼对SW13细胞系的生长抑制作用；流式细胞实验检测其对肾上腺皮质癌细胞系凋亡及细胞周期的影响；Western blot检测埃罗替尼对EGFR下游信号通路蛋白的影响，进一步阐明其作用机制。结果埃罗替尼呈剂量‐时间相关地抑制SW13细胞增殖，药物作用24 h时IC50为20．51μmol／L ；埃罗替尼可以诱导SW13细胞凋亡，处理24 h后，空白组早期凋亡率为（1．62±0．21）％，20μmol／L埃罗替尼治疗组为（13．49±0．48）％，存在统计学差异（P＜0．05）；而埃罗替尼对SW13细胞周期分布无影响。埃罗替尼下调p‐ERK蛋白表达水平，但不影响p‐mTOR表达水平。结论埃罗替尼可以抑制SW13细胞增殖，其作用机制可能与促进凋亡、抑制ERK信号通路有关。
목적：체외탐토EGFR억제제애라체니（Erlotinib）대신상선피질암SW13세포적증식、조망급세포주기적영향。방법응용M T T시험관찰애라체니대SW13세포계적생장억제작용；류식세포실험검측기대신상선피질암세포계조망급세포주기적영향；Western blot검측애라체니대EGFR하유신호통로단백적영향，진일보천명기작용궤제。결과애라체니정제량‐시간상관지억제SW13세포증식，약물작용24 h시IC50위20．51μmol／L ；애라체니가이유도SW13세포조망，처리24 h후，공백조조기조망솔위（1．62±0．21）％，20μmol／L애라체니치료조위（13．49±0．48）％，존재통계학차이（P＜0．05）；이애라체니대SW13세포주기분포무영향。애라체니하조p‐ERK단백표체수평，단불영향p‐mTOR표체수평。결론애라체니가이억제SW13세포증식，기작용궤제가능여촉진조망、억제ERK신호통로유관。
ABSTRACT:Objective To investigate the effect and mechanism of epidermal growth factor receptor (EGFR) inhibitor Er‐lotinib on human adrenocortical carcinoma cell line SW13 in vitro .Methods The proliferation of SW13 after exposure to Er‐lotinib was detected with MTT assay .The apoptosis and cell cycle was determined with Annex‐VI and flow cytometry .The ex‐pression of proteins associated with EGFR signaling were examined with Western blot .Results Erlotinib inhibited SW13 cell proliferation in a dose‐and time‐dependent manner in vitro .The IC50 after exposure of 24 h was 20 .51 μmol/L .Erlotinib in‐duced apoptosis ,cell apoptosis rate in erlotinib 20μmol/L group 24 h was (13 .49 ± 0 .48)% ,significantly higher than that in the control group (1 .62 ± 0 .21)% .Erlotinib had no effect on cell cycle .The expression of p‐ERK was down regulated ,while the expression of p‐mTOR was not affected .Conclusions The proliferation of SW13 cells could be inhibited by Erlotinib , and possible mechanisms involved up‐regulated apoptosis and down‐regulated ERK signaling pathway .